Could Gold Hit a Do...
Health Care: Drugs
Medgenics Inc (MDGN: AMEX)
$4.16 0.09 | 2.21%
05/23/13 - 04:02 PM ET
5.30K / 45.20K
Vol / Avg. Vol:4.06 / 4.07
Open / Prev. Close:4.05 - 4.22
Today's Range:3.66 - 16.43
52 Wk Range:-45.30%
Performance YTD:TheStreet Rating:
Portfolios with MDGN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- UserStocks
Latest MDGN Headlines from TheStreet
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 5 Stocks Under $10 Set to Soar 10.25.12 | 12:10 pm
Press Releases for MDGN
- Medgenics Announces Exercise By Underwriters Of Over-Allotment Option - Business Wire 03.26.13 | 09:03 am
- Medgenics To Present At The 25th Annual Roth Conference - Business Wire 03.15.13 | 09:03 am
- Medgenics Reports 2012 Financial Results - Business Wire 03.14.13 | 09:03 am
- Medgenics Appoints Former Chairman And CEO Of UBS Financial Services Joseph J. Grano, Jr. To Board Of Directors - Business Wire 03.12.13 | 09:03 am
- Medgenics Announces Closing Of Public Offering Of Common Stock And Warrants - Business Wire 02.14.13 | 04:02 am
- Medgenics Prices Public Offering Of Common Stock And Warrants - Business Wire 02.08.13 | 02:02 am
- Medgenics Launches First Clinical Trial In Hepatitis To Use INFRADURE Tissue Treatment - Business Wire 01.30.13 | 07:01 am
- Medgenics, Inc. (the “Company”) Issue Of Options And Restricted Shares To Directors And Officers - Business Wire 01.04.13 | 12:01 pm
- Medgenics Key Patent Claims Allowed In Japan Protecting Core Technology To Be Used In Hepatitis Treatment - Business Wire 12.06.12 | 09:12 am
- Renowned Experts Affirm Potential Of Medgenics’ INFRADURE Technology For The Treatment Of Hepatitis B And D - Business Wire 11.28.12 | 09:11 am
Partner Headlines for MDGN
- Medgenics Wins Patent for Core Technology Used in Sustained Delivery of Erythropoietin - Benzinga 11.21.12 | 09:11 am
- Medgenics Announces Approval of Two Phase I/II Clinical Trials By Israel Regulator - Benzinga 08.29.12 | 01:08 pm
- Medgenics' Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel - Benzinga 08.29.12 | 01:08 pm
- Ultimate Market Recap: Samsung on an Earnings Streak, More iPad Mini Evidence - Wall St. Cheat Sheet 07.06.12 | 09:07 am
- Boston Beer Co. INTRODUCES New Summer Lager and 4 End-of-Week Hot Stocks - Wall St. Cheat Sheet 07.06.12 | 02:07 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Medgenics MOVES Forward with Hepatitis D Drug and 2 More Stocks Hitting 52-Week Highs - Wall St. Cheat Sheet 06.21.12 | 10:06 am
- The Bio Pharma Momentum Movers List For Thursday, June 21 - Seeking Alpha 06.21.12 | 09:06 am
- Medgenics Raises $9.5 Million in Private Placement - Benzinga 06.19.12 | 09:06 am
- Medgenics Raises $9.5 Million in Private Placement - Benzinga 06.19.12 | 09:06 am
